Clinical Trial Update: Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating anlotinib with STUPP for MGMT-unmethylated glioblastoma is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Anlotinib (anlotinib)
• STUPP

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: MGMT-Unmethylated Glioblastoma | Phase 2 | Status: UNKNOWN